obeticholic acid oca sold brand name ocaliva semisynthetic bile acid analogue chemical structure acid used medication used treat primary biliary cholangitis intercept pharmaceuticals inc hold worldwide rights develop oca outside japan china licensed dainippon sumitomo natural bile acid chenodeoxycholic acid identified active physiological ligand farnesoid x receptor fxr involved many physiological pathological processes series alkylated bile acid analogues designed studied patented roberto pellicciari colleagues university perugia acid emerging highly potent fxr fxrdependent processes liver intestine proposed therapeutic targets human obeticholic acid first fxr agonist used human drug studiesmedical citation needed obeticholic acid undergoingwhen development phase ii iii studies specific liver gastrointestinal us food drug administration fda approved obeticholic acid may treatment primary biliary cholangitis approved orphan drug based reduction level biomarker alkaline phosphatase surrogate endpoint clinical indicated treatment primary biliary cholangitis combination ursodeoxycholic acid adults inadequate response udca monotherapy adults unable tolerate additional studies required prove clinical primary biliary cholangitis pbc also known primary biliary cirrhosis autoimmune inflammatory liver disease produces bile duct injury fibrosis cholestasis eventual much common women men cause jaundice itching pruritus fatigue ursodeoxycholic acid therapy beneficial disease often progresses may require liver animal studies suggested treatment fxr agonists beneficial cholestatic diseases oca doses mg mg shown provide significant biochemical benefit pruritus frequent higher results randomized doubleblind phase iii study oca mg mg compared placebo poise presented april showed drug met trials primary endpoint significant reduction serum alkaline phosphatase biomarker predictive disease progression liver transplantation nonalcoholic steatohepatitis common cause abnormal liver function histological features fatty liver inflammation fibrosis may progress cirrhosis becoming increasing indication liver transplantation increasing prevalence oca proposed treat phase ii trial published showed administration oca mg mg daily six weeks reduced markers liver inflammation fibrosis increased insulin farnesoid x receptor ligand obeticholic acid nonalcoholic steatohepatitis treatment flint trial sponsored niddk halted early january half subjects completed study planned interim analysis showed primary endpoint met b lipid abnormalities detected arose safety concerns treatment oca mgday weeks resulted highly statistically significant improvement primary histological endpoint defined decrease nafld activity score least two points worsening fibrosis treated group improvement compared placebotreated however concerns longterm safety issues increased cholesterol adverse cardiovascular events may warrant concomitant use statins ocatreated fda panel voted approval obeticholic acid nash citing lack evidence benefits drug outweighed animal studies suggest oca improves intrahepatic vascular resistance may therapeutic benefit portal open label phase iia clinical study waywhencitation needed bile acid diarrhea also called bile acid malabsorption secondary crohns disease primary condition reduced median levels ileal hormone regulates increased hepatic bile acid synthesis found potently stimulated bile acids especially proof concept study oca mgd shown clinical biochemical february fda updated label warnings obeticholic acid better explain recommended dosing according agency misunderstanding led health care professionals improperly dose drug daily basis rather weekly increase risk liver httpsenwikipediaorgwikiobeticholicacid